Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Influenza
Interventions: CAIV-T, TIV; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more

Conditions: Control - No Incentive for Flu Vaccine, Direct Incentive, Indirect Incentive
Interventions: Email Message, Incentive for Vaccination, Incentive for completing a short survey; Behavioral
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12,531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: H1N1 Flu
Interventions: HAC1 Vaccine; Biological
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza
Interventions: Fluzone®: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza A Subtype H5N1 Infection
Interventions: H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine; Biological
Lead sponsor: Access to Advanced Health Institute (AAHI); Other
Eligibility: 18 Years to 49 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Influenza
Interventions: AV024, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Vaccination, Influenza
Interventions: Local educational information, National educational information; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Upper Respiratory Infection
Interventions: BD Veritor At-Home, BD Veritor Professional; Diagnostic Test
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 2 Years and older
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Coconut Creek, Florida • Palm Springs, Florida • Pembroke Pines, Florida + 6 more

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more

Conditions: Influenza
Interventions: Inactivated H1N1 vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Inactivated influenza vaccine, Placebo; Biological · Other
Lead sponsor: Mark Prausnitz; Other
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: Digital storytelling; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 90 Years
Enrollment: 398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Denver, Colorado

Conditions: Pandemic Influenza
Interventions: H5N1 VLP Vaccine, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: Oseltamivir, MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Influenza Virus Vaccine
Interventions: Trivalent Inactivated Influenza vaccine; Biological
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years and older
Enrollment: 971 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more

Conditions: Influenza
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 49 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza
Interventions: VRC-FLUNPF0103-00-VP (H10ssF-6473); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions: Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more

Conditions: Influenza
Interventions: Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Search by objective public record fields.

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Non-integrated Costs Increase Effectiveness of Incentives

Study of the Safety and Immunogenicity of H1N1 Vaccine

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

Influenza Vaccine Randomized Educational Trial: Adult

BD Veritor™ At-Home and BD Veritor™ Professional

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults